ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Severe Depressive Illness by Targeted Brain Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01101373
Recruitment Status : Completed
First Posted : April 9, 2010
Last Update Posted : April 9, 2010
Sponsor:
Information provided by:
University of British Columbia

April 8, 2010
April 9, 2010
April 9, 2010
October 2000
November 2009   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Treatment of Severe Depressive Illness by Targeted Brain Surgery
Bilateral Anterior Capsulotomy For Intractable Depression
This study will report on the outcome of a clinical program, operational since 1998, that has used surgery targeting an emotional pathway in the brain in the treatment of severe depressive illness that has failed to respond to all other available interventions. Benefit from surgery was anticipated on the basis that the lesion (bilateral anterior capsulotomy) is a well established surgical target for treating severe treatment resistant depression.
Since 1998 bilateral anterior capsulotomy (BAC) has been available to patients in British Columbia Canada who have treatment refractory severe depressive illness. This study will report on the outcome of patients who have received this intervention. BAC is achieved by stereotactic radiofrequency lesioning. To date 8 patients have received BAC. For all patients there is follow-up data of at least 24 months. The purpose of this retrospective study is to report on the surgical protocol and to demonstrate the efficacy and safety of BAC in severe depression.
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
All subjects who received BAC for treatment resistant depression between 2000 and 2009
Major Depressive Disorder
Not Provided
1
All subjects who received BAC for treatment resistant depression between 2000 and 2009
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
April 2010
November 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Severe treatment resistant depression of at least 5 years duration
  • older than 18 years

Exclusion Criteria:

  • Comorbid organic mental disorder
  • Delusional disorder
  • Substance disorder
  • Neurological disease
  • Cluster B personality disorder
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT01101373
H10-00851
No
Not Provided
Not Provided
Dr. Trevor Hurwitz, University of British Columbia - Vancouver Coastal Health Research Institute
University of British Columbia
Not Provided
Study Director: Christopher Honey, MD University of British Columbia
Study Director: Judy Allen, MD University of British Columbia
Study Director: Robert Hewko, MD University of British Columbia
Study Director: Caroline Gosselin, MD University of British Columbia
Study Director: Nicolas Bogod, MD University of British Columbia
Study Director: Jeff Martzke, MD University of British Columbia
Study Director: Patricia Taylor University of British Columbia
University of British Columbia
April 2010